Objective-Gene therapy, delivered directly to the blood vessel wall, could potentially prevent atherosclerotic lesion growth and promote atherosclerosis regression. Previously, we reported that a helper-dependent adenoviral (HDAd) vector expressing apolipoprotein A-I (apoA-I) in carotid endothelium of fat-fed rabbits reduced early (4 weeks) atherosclerotic lesion growth. Here, we tested whether the same HDAd-delivered to the existing carotid atherosclerotic lesions-could promote regression. Approach and Results-Rabbits (n=26) were fed a high-fat diet for 7 months, then treated with bilateral carotid gene transfer.
A therosclerosis, a chronic disease of medium and large arteries, is characterized by subendothelial accumulation of lipids, lipid-laden macrophages, and lipid-laden smooth muscle cells. 1 Current medical therapy aimed at reversing atherosclerosis or halting its progression is essentially limited to drugs (such as statins) that lower plasma low-density lipoprotein cholesterol, thereby decreasing lipid entry into the artery wall. Low-density lipoprotein-lowering drugs are useful; however, they are only partially effective, require life-long adherence to a daily dosing regimen, and are poorly tolerated by many. [2] [3] [4] A new therapy for lowering plasma low-density lipoprotein cholesterol, antibodies that inhibit proprotein convertase subtilisin kexin 9, is expensive (>$14 000 per year versus <$50 per year for some statins), 5 requires biweekly injections for life, and has not yet shown an impact on patient outcomes. 6, 7 Drugs that increase plasma high-density lipoprotein (HDL) cholesterol are theoretically a complementary approach to the treatment of atherosclerosis. 8, 9 Drug-induced increases in plasma HDL are expected to prevent and reverse atherosclerosis by increasing HDL-mediated removal of cholesterol from cells of the artery wall, a process termed cholesterol efflux. 10, 11 However, HDL-raising drugs such as niacin and cholesterol ester transfer protein inhibitors have failed repeatedly in clinical trials. [12] [13] [14] [15] Negative results with these drugs-despite impressively elevated plasma HDL levels in treated patientsmight be accounted for by off-target effects or by the failure of these drugs to reliably and robustly accelerate cholesterol efflux in vivo. [16] [17] [18] [19] Numerous studies establish that apolipoprotein A-I (apoA-I), the most abundant protein in HDL, 20 is the component of HDL that is responsible for stimulating cholesterol efflux. 9, 21, 22 ApoA-I stimulates cholesterol efflux both as a constituent of HDL particles and as a free protein. 23 Accordingly, apoA-I has been tested as a therapy for atherosclerosis both in animals (initially in transgenic mice) and in humans (as a brief protein infusion) and has shown efficacy in both settings. [24] [25] [26] [27] For example, every-other-day subcutaneous injections of apoA-I in apoE-null mice decreased lesion lipids and macrophages (but not lesion volume) within 1 week, 28 and weekly infusions of apoA-I-containing reconstituted HDL in humans decreased coronary lesion volume by ≈5% within 5 weeks. 29 Unfortunately, these experimental apoA-I therapies are not currently translatable into clinical care because transgenesis of humans is neither ethical nor feasible, and lifetime injections or infusions of apoA-I protein (which would likely be required to maintain the effects of acute treatment) are both prohibitively expensive and impractical. Other approaches aimed at exploiting atheroprotective activities of lipid-poor apoA-I include apoA-I-mimetic peptides 30 (some of which are orally bioavailable) and reconstituted complexes of human apoA-I and phosphatidylcholine (delivery intravenously). 31 These approaches are promising but are not yet proven clinically. Both would require repeated administration and are likely to be costly.
In contrast, a single dose of gene therapy with an apoA-I-expressing vector could potentially provide durable-if not lifetime-in vivo delivery of apoA-I protein. Moreover, introduction of apoA-I-expressing vectors directly to the artery wall would result in synthesis and release of lipid-poor apoA-I protein precisely where it is most needed: adjacent to a lipid-rich atherosclerotic plaque. To this end, we constructed a helper-dependent adenoviral (HDAd) vector that expresses rabbit apoA-I, 32 and we showed that HDAd expressing apoA-I (HDAdApoAI) stimulated cholesterol efflux in vitro and expressed apoA-I for at least 48 weeks in carotid arteries of chow-fed rabbits. HDAdApoAI also significantly retarded development of early carotid atherosclerosis in fat-fed rabbits. 33 Here, we address the more clinically relevant question of whether HDAdApoAI can promote regression of established atherosclerotic lesions. We treated rabbit carotid atherosclerotic lesions by intraluminal delivery of HDAdApoAI or a control vector (nonexpressing HDAd [HDAdNull] ). After 7 weeks of gene therapy, we compared lesion size, lipid content, cellular composition, and adhesion molecule expression in HDAdApoAI-and HDAdNull-treated arteries.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Responses to Initiation and Cessation of Atherogenic Diet
We enrolled 34 rabbits in the study by switching them from regular chow to a high-fat diet ( Figure 1 ). We measured plasma cholesterol after 1 month of this diet and then every 2 weeks. As expected, 34 plasma cholesterols substantially and maintained the majority of rabbits in the targeted 200 to 800 mg/dL range during the period of lesion progression (4-28 weeks). We targeted the 200 to 800 mg/dL range to avoid build-up of hepatic cholesterol stores, which occurs when rabbits are more aggressively fat fed, 35 and which renders them resistant to atherosclerosis regression. 36 Of the 34 rabbits, 3 were euthanized because of surgical complications or disease unrelated to this study (see Materials and Methods in the online-only Data Supplement); all others completed the study. Three rabbits had evidence of dietary toxicity, manifested as particularly high plasma cholesterol levels, low hematocrits, and loss of appetite. These 3 rabbits were switched to a normal chow diet, on which these issues resolved, and they were continued in the study. Cholesterol levels were 1060±468 mg/dL at the time of lesion initiation (ie, DMEM infusion at 4 weeks), 431±180 mg/dL at the time of lesion treatment (ie, vector infusion, typically at 28 weeks), and 117±63 mg/dL at vessel harvest (typically at 35 weeks; Figure I in the online-only Data Supplement). A metabolic panel and complete blood count were performed on 8 rabbits at 35 weeks: nearly all of the mean values were within reported normal ranges for New Zealand White rabbits (Table I in the online-only Data Supplement).
We switched the rabbits to a chow diet at the time of vector delivery for 2 primary reasons. First, we aimed to rigorously test vascular gene therapy by administering it on a background of aggressive lipid lowering. At present, all humans who are candidates for atherosclerosis regression therapy would first be given a lipid-lowering drug and would continue this as tolerated. Accordingly, for vascular gene therapy to be widely useful, it must be effective on a background of systemic lipidlowering therapy. Eventually vascular apoA-I gene therapy might replace systemic therapy, but that is a question for the future. Second, we aimed to test whether apoA-I could accelerate lesion regression. Continuing the high-fat diet would likely have caused lesion progression, and our study would have measured effects of apoA-I on progression, not regression.
Persistence of HDAd Genomes and ApoA-I Expression in HDAdApoAI-Transduced Arteries
After 28 weeks of high-fat diet, all rabbits received bilateral common carotid infusions: HDAdApoAI in one carotid and HDAdNull in the other (Figure 1 ). Our vector infusion protocol (described in more detail in Materials and Methods in the online-only Data Supplement) uses a surgical approach to isolate carotid artery segments from the circulation followed by rinsing of the isolated artery lumens and infusion of the vector in the absence of blood. The vector is then withdrawn and blood flow re-established. The side infused with each vector (left or right) was randomized for every rabbit. This aspect of our experimental design eliminates plasma lipid and lipoprotein levels as an independent variable because the left and right arteries in each rabbit are exposed to identical concentrations of plasma lipids and lipoproteins. We-and othershave reported that infusion of adenoviral vectors into isolated carotid artery segments (in both normolipidemic and hyperlipidemic animals) results in gene transfer almost exclusively to luminal endothelial cells in the transduced segments. [37] [38] [39] Moreover, in rabbits infused with HDAdApoAI according to this protocol, we were unable to detect the HDAdApoAI vector genome in any tissue other than the transduced artery segments. 33 Therefore, this protocol tests the effects of local apoA-I expression in luminal endothelial cells.
To evaluate gene transfer into the existing atherosclerotic lesions, we euthanized 5 rabbits on the third day after vector infusion and measured HDAd genomes and apoA-I mRNA in carotid artery extracts. Vector genomes were detected in all 10 arteries (median [interquartile range]=9 genomes per vascular wall cell; Figure 2A ). This level of genomes is similar to the level of genomes found 3 days after vector infusion into arteries of chow-fed rabbits. 40 ApoA-I mRNA was present in all HDAdApoAI-infused arteries removed 3 days after infusion and in none of the HDAdNull-infused arteries ( Figure 2B ). We also measured vector genomes and apoA-I mRNA in arteries removed at the end of the study (7 weeks after vector infusion). Vector genomes remained far above background in all arteries (0.9 [0.5-1.4] vector genomes per vascular wall cell; n=52; Figure 2A ). ApoA-I mRNA was detected in all 26 HDAdApoAI-infused arteries harvested 7 weeks after vector infusion. Levels of apoA-I mRNA were lower than at 3 days but still well above background. Absence of apoA-I mRNA in HDAdNull-infused arteries confirms (1) no meaningful level of apoA-I gene transfer occurs contralateral to HDAdApoAI infusion and (2) in the unlikely event that any cells in the peripheral blood or bone marrow are transduced by small amounts of systemically released HDAdApoAI vector, none of these cells can be detected in the artery wall. The levels of apoA-I mRNA at 3 days and 7 weeks were similar to levels of apoA-I mRNA that we measured 3 days and 4 weeks, respectively, after infusion of HDAdApoAI in rabbits with developing atherosclerotic lesions (data not shown). This earlier study 33 showed significant therapeutic effects of HDAdApoAI on early lesion growth.
ApoA-I protein was present in medium conditioned by 21 of the 26 HDAdApoAI-infused arteries harvested 7 weeks after vector infusion. In contrast, ApoA-I protein was present in medium conditioned by only 3 of the 26 HDAdNull-infused arteries (P<0.001; Figure 2C ; Figure II in the online-only Data Supplement). The low levels of apoA-I protein in the 3 HDAdNull samples presumably are because of ex vivo release of plasma apoA-I that was not completely washed out before placing the arteries in explant culture (see Materials and Methods in the online-only Data Supplement). Matched plasma samples collected from each rabbit before vector infusion and at harvest 7 weeks later showed no evidence that plasma apoA-I levels were altered by the HDAdApoAI infusion (P=0.7 for comparison of preinfusion and postinfusion band densities by Western blotting; Figure III in the onlineonly Data Supplement).
Effects of HDAdApoAI on Intimal Area, Lipid, Macrophage, and T-Cell Content
We confined our tissue analyses to the 2 transduced carotid arteries because the experiments were designed to compare local effects of HDAdApoAI to local effects of HDAdNull in different arteries of the same rabbit. We did not examine other vessels because (1) no other vessels were treated with HDAdApoAI, (2) we found no evidence that levels of plasma apoA-I protein were altered by local infusion of HDAdApoAI, and (3) there was no control group against which vessels other than the infused carotids could be compared.
Intimal lesions were present in all 52 arteries. Median intimal areas in both groups (null: 150 000 µm 2 ; ApoA-I: 86 000 µm 2 ; Table 1 ) were far below the median intimal area of recent historical control arteries (median lesion area=240 000 µm 2 ). These historical control arteries were from rabbits that also underwent bilateral carotid infusions of DMEM after 4 weeks of high-fat diet but were harvested at the 28-week time point instead of receiving infusions of HDAd. 34 The smaller intimal areas in this study suggest that our protocol of dietinduced lowering of plasma cholesterol promoted regression of atherosclerosis in both groups. Consistent with findings of the study in which we developed this model, 34 lesion size was highly variable with intimal areas ranging from 355 to 550 000 µm 2 in individual arteries. This variability, along with the high correlation of intimal areas between left and right arteries in the same rabbit (r=0.7; P<0.0002; Figure IV in the online-only Data Supplement), supported our prospective decision to use a paired sample study design for the final data analysis. According to this design, we first calculated and compared overall HDAdNull and HDAdApoAI group medians (Table 1) . However, to test for statistical significance of effects of apoA-I expression, we compared HDAdApoAIand HDAdNull-treated arteries in the same rabbits. We used a ratio-paired test to test the null hypothesis that the median ratio of values in paired arteries (ie, value in HDAdApoAItreated artery/value in HDAdNull-treated artery in the same rabbit) was 1.
As expected, 34 intimal lesions were rich in lipid and macrophages ( Figure 3B , 3C, 3F, and 3G). The lesions also contained smooth muscle cells, typically in a lesion cap ( Figure 3D and 3H), and rare T cells (Figure V in the online-only Data Supplement). Median intimal area, intimal/medial area ratio, Oil Red O (ORO)-stained area, and area stained for the macrophage marker RAM-11 or the T-cell marker KEN-5 were all nominally lower in the group of 26 HDAdApoAI-treated arteries compared with the group of 26 HDAdNull-treated arteries (32%-49% lower; Table 1 ; left-most data columns). We also found less intimal area, intimal/medial area ratio, ORO-stained area, RAM-11-stained area, and KEN-5-stained area in the 26 HDAdApoAI-treated arteries compared with their paired HDAdNull-treated controls (median reductions of 7%-25%; Table 1 , third data column). These data are consistent with reduced atherosclerosis in HDAdApoAI-treated arteries versus paired HDAdNull-treated controls; however, none of the reductions is statistically significant (P=0.2-0.4; Table 1 ). The percentages of intimal area staining for ORO, RAM-11, and KEN-5 were similar between the 2 groups (1%-2% absolute differences; Table 1 ) and were nominally less in HDAdApoAI-treated arteries versus their paired controls (median 5%-14% reductions; P=0.2-0.4; Table 1 ).
To determine if expression of apoA-I affected lesion macrophage phenotype (as reported after injection of apoA-I protein in mice), 28 we measured interleukin-1β and MRC1 (mannose receptor, C type 1) mRNA in lesion extracts (interleukin-1β and MRC1 are markers of macrophage M1 and M2 phenotype, respectively). 41 Median interleukin-1β mRNA was 34% lower in the group of HDAdApoAI-treated arteries than the group of HDAdNull-infused arteries; median MRC1 mRNA was 7% higher in HDAdApoAItreated arteries. When compared with their paired HDAdNull-treated controls, HDAdApoAI-treated arteries had 14% lower median interleukin-1β mRNA expression (P=0.4) and 8% higher median MRC1 mRNA expression (P=0.4). Attempts to measure several other proposed rabbit M1 and M2 markers by quantitative reverse-transcriptasemediated polymerase chain reaction 41 were not successful.
Effects of HDAdApoAI on Medial Area and Intimal Smooth Muscle Area
Because atherosclerosis is primarily an intimal disease, 1 atheroprotective effects of apoA-I would likely be confined to the intima. Consistent with this, medial areas were nearly identical both between the 2 groups and between HDAdApoAI-treated arteries and their paired HDAdNulltreated controls (6% difference between group medians; 0% median difference between paired arteries; P=1.0; Table 1 Figure 4D ). The median percentage of intimal area staining for smooth muscle actin was identical between the 2 groups of arteries (Table 1) and only 5% less in HDAdApoAI-treated arteries than their HDAdNull-treated controls (P=0.9; Table 1 ). The combined percentage of intimal area occupied by macrophages, T cells, and smooth muscle cells was essentially identical in both groups (60% and 61%).
Post hoc Subgroup Analysis of Smallto-Moderate-Sized Lesions
The full data set ( Figure 4 ) suggested that HDAdApoAI might have a therapeutic effect on small-to-moderate-sized lesions but not on large lesions (note the preponderance of gray data points in the upper part of each panel and black data points in the lower part). To explore this possibility, we performed a post hoc subgroup analysis that excluded 6 rabbits in which either the left or right carotid artery had an intimal area >1 SD above the mean of all arteries ( Figure 5 ; Figure  VD in the online-only Data Supplement; Table 2 ). In this subgroup of 20 rabbits, the group of HDAdApoAI-treated arteries had substantially lower median intimal areas and intimal/medial area ratios than the group of HDAdNull-infused arteries (54% lower for both; Figure 5A through 5C; Table 2 ; left-most data columns). The median reductions in intimal area and intima/media area ratios in HDAdApoAI-treated arteries compared with their paired HDAdNull-treated controls were also large (36% and 34%) and were statistically significant (P=0.04 for both; Table 2 ). HDAdApoAI-treated arteries in this subgroup also had far less median intimal ORO, RAM-11 (macrophage), and KEN-5 (T cell) staining than HDAdNull arteries (74%, 68%, and 49% less; Table 2 ). The median reductions in intimal ORO-stained and RAM-11-stained areas in HDAdApoAI-treated arteries compared with their paired HDAdNull-treated controls were also substantial (30% and 29%) and either met or approached statistical significance (P=0.03 and P=0.06, respectively; Table 2 ). KEN-5 staining was reduced by 34% in paired HDAdApoAItreated arteries (P=0.2; Table 2 ; Figure VD in the online-only Data Supplement). The percentages of intimal area staining for ORO, RAM-11, and KEN-5 were similar between the 2 groups of arteries. Compared with paired HDAdNull controls, HDAdApoAI-treated arteries had a 15% reduction in percent ORO-stained area (P=0.5), a 12% increase in percent KEN-5-stained area (P=0.8), and no change in percent RAM-11-stained area ( Table 2 ). The combined percentage of intimal area occupied by macrophages, T cells, and smooth muscle cells was similar between the 2 groups (59% for HDAdNulltreated and 64% for HDAdApoAI-treated arteries). Therefore, the smaller intimal areas in HDAdApoAI-treated arteries did not result from a disproportionate decrease in intimal cellularity. Medial areas in this subgroup were similar between the HDAdApoAI-treated and HDAdNull-treated arteries (9% difference in group medians; 5% median difference between paired arteries; P=0.1; Table 2 ). The median intimal area staining for smooth muscle actin was nominally less in the HDAdApoAI-treated arteries than the HDAdNull-treated arteries (67% decrease in group medians; 52% median decrease in paired HDAdApoAI-treated versus HDAdNulltreated arteries; P=0.1; Figure 5D ; Table 2 ). The median percentage of smooth muscle actin-stained intimal area was nearly identical between the group of HDAdApoAI-treated arteries and the group of HDAdNull-treated arteries (12% and 13%, respectively; Table 2 ). There was no difference in median percentage of smooth muscle actin-stained intimal area between the HDAdApoAI-treated arteries and their paired HDAdNull-treated controls (0%; P=1.0).
HDAdApoAI Significantly Reduces Intimal Vascular Cell Adhesion Molecule-1 Expression
Vascular cell adhesion molecule-1 (VCAM-1) staining was observed in luminal endothelial cells and deeper within the intima ( Figure 3I ). Intercellular adhesion molecule-1 (ICAM-1) staining was present along the lumen and deeper within the intima (Figure 3J) , where it colocalized with RAM-11 staining detected on nearby sections (not shown). The group Table 1 ). The median reductions in intimal VCAM-1 and ICAM-1 staining in HDAdApoAI-treated arteries compared with paired HDAdNull controls were 28% and 21%, respectively. The reduction in VCAM-1 expression was statistically significant (P=0.04; Table 1 ). In the 20 rabbits with small-to-moderate lesions, the group of HDAdApoAIinfused arteries had far less median intimal VCAM-1-stained and ICAM-1-stained areas than the group of HDAdNullinfused arteries (61% and 55% decreases; Table 2 ). The median reductions in intimal VCAM-1 and ICAM-1 staining in HDAdApoAI-treated arteries compared with their paired HDAdNull-treated controls were also large (42% and 47%, respectively; P=0.03 and 0.02; Table 2 ).
For both the entire set of arteries and the subgroup with small-to-moderate lesions, percentages of intimal area staining for VCAM-1 and ICAM-1 were lower in the group of HDAdApoAI-treated arteries (15%-21%; Tables 1 and 2 ). There were similar differences between HDAdApoAI-treated arteries and their paired HDAdNull-treated controls (12%-28% median reductions in HDAdApoAI arteries), but none of these differences reached statistical significance (P≥0.1 for all; Tables 1 and 2 ).
Discussion
We used a rabbit model of carotid artery atherosclerosis to test whether local gene therapy with an apoA-I-expressing vector could regress atherosclerotic lesions. Our major findings were (1) infusion of HDAdApoAI into atherosclerotic arteries yielded substantial apoA-I expression, (2) 7 weeks of apoA-I expression in atherosclerotic arteries significantly reduced VCAM-1 expression, (3) 7 weeks of apoA-I expression in atherosclerotic arteries did not significantly accelerate atherosclerotic lesion regression, as measured by total intimal area or by lipid or macrophage content of the intima, and (4) post hoc subgroup analysis of small-to-moderate-sized atherosclerotic lesions revealed statistically significant acceleration of lesion regression in HDAdApoAI-treated arteries, including a median ≈35% decrease in total intimal area and intimal:medial area ratio, 30% decreases in lesion lipid and macrophage content, and 40% to 50% decreases in intimal adhesion molecule expression.
Beginning over 20 years ago, several groups showed that germ line transgenic overexpression of apoA-I retards the development of atherosclerosis. 25, 42, 43 Subsequent reports established that postnatal apoA-I gene therapy-delivered either by systemic injection of vectors targeting the liver or by infusion of ex vivo transduced bone marrow-derived cells-can both suppress and regress experimental atherosclerosis. [44] [45] [46] [47] Despite these impressive results, there are several reasons why neither of these approaches has advanced to the clinic: (1) systemic injection of large amounts of viral vectors is toxic, 48 (2) transgene expression is gradually lost after hepatocyte gene transfer, likely because of cell turnover, 49 (3) in humans, even the most advanced approaches to hepatocyte gene transfer require immunosuppression to maintain transgene expression, 50 and (4) the risks to patient well-being of radiation and bone marrow transplantation outweigh the potential benefits of slowing atherosclerosis progression. The approach used in this study has the potential to avoid all of these limitations because local infusion of HDAd to the artery wall is minimally toxic, 51 yields transgene expression that seems to last indefinitely (without immunosuppression), 33 does not require marrow-ablative chemotherapy, and has a minimal risk of genotoxicity due to use of adenovirus, a nonintegrating vector. Moreover, transduction of vascular cells-predominantly endothelial cells in this model [37] [38] [39] -delivers lipid-poor apoA-I directly to the site of atherosclerotic disease. Direct vessel wall delivery of apoA-I should be a particularly effective means of stimulating efflux of cholesterol from atherosclerotic arteries because lipid-poor apoA-I and minimally lipidated apoA-I are superior acceptors of cholesterol compared with the more lipidated apoA-I forms that circulate in animals with hepatic apoA-I overexpression. 23, 52 In addition, continuous synthesis of apoA-I in the artery wall might avoid oxidative damage that impairs the function of liver-derived apoA-I that circulates in plasma and accumulates in the artery wall. 53 These theoretical advantages were supported by experiments in our laboratory showing that focal artery wall expression of apoA-I significantly reduces development of early (1 month) atherosclerosis in fat-fed rabbits. 33 Here, we asked whether vascular wall delivery of apoA-I could promote atherosclerosis regression. This is a clinically relevant question because gene therapy for atherosclerosis will likely be used to treat established atherosclerosis in patients at high risk for clinical events before it will be tried as a preventive measure. To test whether vascular apoA-I gene therapy promotes atherosclerosis regression, we first developed a rabbit model of focal severe carotid atherosclerosis. 34 This model yields large intimal lesions that are macrophage and lipid rich, but also contain smooth muscle cells, often in a fibrous cap. These lesions resemble mature human plaques and are-as noted by others 46 -a more clinically relevant target than the early fatty streaks present in many mouse models and in our rabbit model of atherosclerosis progression. 33 The approach used in this study relies on efficient gene transfer to these complex lesions. Although others reported low gene transfer efficiency to atherosclerotic rabbit arteries, 54 we found that apoA-I expression in the atherosclerotic arteries was equivalent to the level we reported in arteries of chow-fed rabbits 33 (data not shown). Arteries infused with HDAdApoAI had significantly less staining for VCAM-1 than control-transduced arteries. All other end points (intimal area, intima/media area ratio, lipid and macrophage accumulation, ICAM-1, and KEN-5 expression) trended toward efficacy; however, the effects were relatively small (≈10%-20% decreases) and not statistically significant. We considered several explanations for why the salutary effects of apoA-I were not larger and more consistently significant. First, lesion size in this model is highly variable, making it difficult for small-to-moderate therapeutic effects to achieve statistical significance. Much of the variability derives from rabbit-specific factors, as is evident from the high left-right lesion size correlation in individual rabbits ( Figure IV in the online-only Data Supplement). We minimized the contribution of individual rabbit variability using a left-right paired analysis; however, even with this approach, all end points varied widely. Second, we tested apoA-I gene therapy on a background of the highly effective intervention of plasma cholesterol lowering (because of cessation of the high-fat diet). During 7 weeks of gene therapy, mean plasma cholesterols decreased by >70%, with many rabbits entering the normal range. This design is rigorous and clinically relevant because humans with atherosclerosis are routinely treated with cholesterollowering medications. However, it may be difficult to detect additive effects of gene therapy on this background. Third, our experimental intervention was brief (7 weeks). Others have detected atherosclerosis regression in as little as 4 weeks, including in rabbits treated systemically with HDL (but maintained on a high-fat diet). 55, 56 Longer treatment might have revealed larger effects of apoA-I gene therapy, especially on larger lesions.
After examining our initial results, we considered another possible explanation for the modest overall effects of apoA-I: that robust therapeutic effects of apoA-I on small-to-moderate lesions were overwhelmed by a lack of apoA-I effects on large lesions. Larger lesions are typically more complex and inherently more resistant to regression. 36 In addition, our therapeutic approach is based on delivery of apoA-I from a single layer of endothelial cells overlying a plaque. As plaques enlarge, the ratio of endothelial surface:lesion volume decreases in proportion to lesion size. Consequently, in large lesions, the intralesional concentration of apoA-I is lower, and the distance that apoA-I protein must travel to reach all lesional cells is greater. Both factors would mitigate therapeutic efficacy.
To test the hypothesis that efficacy of our therapy depends on lesion size, we performed a post hoc subgroup analysis that excluded rabbits (6 of 26) that had at least 1 lesion with intimal area >1 SD above the group mean. In this subgroup of lesions, apoA-I gene therapy positively impacted all end points, with near-uniform statistical significance. To further test this hypothesis, 57 we directly compared HDAdApoAI efficacy in large lesions versus small-to-moderate lesions and found a statistically significant interaction between lesion size and response to HDAdApoAI (P=0.02; Figure VI in the online-only Data Supplement). Interactions between lesion size and response to HDAdApoAI were either significant or borderline significant for ORO area, RAM-11 area, and ICAM-1 area (P=0.04-0.08; Figure VII in the online-only Data Supplement). Nevertheless, because we identified the lesion size subgroups post hoc, we view these results cautiously and plan to test them prospectively. Prospective testing could be done by repeating the study with exclusion of the largest lesions from the final analysis. Alternatively, we could perform premortem screening with noninvasive means such as transcutaneous ultrasound or magnetic resonance imaging and censor rabbits with large lesions. We are aware that gene therapy to promote atherosclerosis regression should be effective on large and small lesions. This is our goal; however, it may require higher levels of apoA-I expression, longer duration of treatment, or both.
We carefully considered the possibility that the initial study was truly negative and that HDAdApoAI gene therapy does not promote lesion regression. There are 4 reasons why we think this is unlikely. First, in the paired analyses of both the entire group of 26 rabbits and the subgroup of 20 rabbits, 100% (7 of 7) measurements of intimal mass, intimal/medial area ratio, lipid accumulation, macrophage and T-cell accumulation, and adhesion molecule expression were decreased in HDAdApoAI-treated arteries. Second, VCAM-1 staining, which was significantly decreased by HDAdApoAI in the full 26 rabbit cohort, is a highly reproducible biochemical marker of apoA-I activity. 32, 46, [58] [59] [60] Third, treatment with HDAdApoAI had far greater effects on intimal area, lipids, and macrophages than it did on the vascular media, consistent with its known biological effects. Fourth, the subgroup analysis, though post hoc, has a rational basis: the physical principles that govern surface:volume ratio mandate that apoA-I delivery to large lesions is less efficient. Moreover, this was the only subgroup analysis we performed. On the other hand, HDAdApoAI did not significantly alter the relative percentages of intimal cell types (eg, by decreasing % lesion macrophage area or increasing % lesion smooth muscle cell area, resulting in a more stable lesion phenotype). This could be viewed as a reason to doubt efficacy; however, absence of such effects could be because of apoA-I-mediated removal of lipid from both macrophages and smooth muscle cells, decreasing intimal area occupied by both cell types. Alternatively, this 7-week study may have been too brief to detect changes in relative cellular composition of the lesions. Finally, because lesion cellular composition is a calculated quantity that incorporates 2 measurements (and their measurement errors), it is more variable than area measurements and less amenable to the detection of significant differences.
In conclusion, our initial test of whether vascular walltargeted apoA-I gene therapy could promote atherosclerosis regression yielded results that are encouraging but not definitive. Our results are exciting in that they show-for the first time-that vector delivery to established complex atherosclerotic lesions is feasible, safe, durable and is likely effective. A therapy that complemented the relatively modest effects of current drug therapy on atherosclerosis regression 55 would have a major impact on human health. Moving vascular wall-targeted HDAd gene therapy into the clinic will require more convincing proof of efficacy, advances in vector delivery techniques, and viral capsid engineering that circumvents widespread human immunity to type V adenovirus. 61 These are daunting challenges; however, progress is being made in both of the latter areas. 62, 63 Vascular wall gene therapy that is delivered by a single infusion and reverses human atherosclerosis is beginning to seem feasible.
